Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74.
World Well being Group. 2023. https://covid19.who.int.
Guo D, Han B, Lu Y, Lv C, Fang X, Zhang Z, et al. Affect of the COVID-19 pandemic on high quality of lifetime of sufferers with Parkinson’s illness. Parkinsons Dis. 2020;2020:1216568.
Koelle Ok, Martin MA, Antia R, Lopman B, Dean NE. The altering epidemiology of SARS-CoV-2. Science. 2022;375:1116–21.
Davis HE, McCorkell L, Vogel JM, Topol EJ. Lengthy COVID: main findings, mechanisms and suggestions. Nat Rev Microbiol. 2023;21:133–46.
Tune E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-CoV-2 in human and mouse mind. J Exp Med. 2021;218:e20202135.
Emmi A, Rizzo S, Barzon L, Sandre M, Carturan E, Sinigaglia A, et al. Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei. NPJ Parkinsons Dis. 2023;9:25.
Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The rising spectrum of COVID-19 neurology: scientific, radiological and laboratory findings. Mind. 2020;143:3104–20.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized sufferers with coronavirus illness 2019 in Wuhan, China. JAMA Neurol. 2020;77:683–90.
Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort research utilizing digital well being data. Lancet Psychiatry. 2021;8:416–27.
Grayson M. Parkinson’s illness. Nature. 2016;538:S1.
Simon DK, Tanner CM, Brundin P. Parkinson illness epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med. 2020;36:1–12.
Pang SY, Ho PW, Liu HF, Leung CT, Li L, Chang EES, et al. The interaction of ageing, genetics and environmental elements within the pathogenesis of Parkinson’s illness. Transl Neurodegener. 2019;8:23.
Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a scientific assessment. J Neurol Sci. 2020;413:116832.
Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Speedy and long-term penalties of COVID-19 infections for the event of neurological illness. Alzheimers Res Ther. 2020;12:69.
Merello M, Bhatia KP, Obeso JA. SARS-CoV-2 and the chance of Parkinson’s illness: details and fantasy. Lancet Neurol. 2021;20:94–95.
Boura I, Chaudhuri KR. Coronavirus illness 2019 and associated Parkinsonism: the scientific proof so far. Mov Disord Clin Pract. 2022;9:584–93.
Soung AL, Vanderheiden A, Nordvig AS, Sissoko CA, Canoll P, Mariani MB, et al. COVID-19 induces CNS cytokine expression and lack of hippocampal neurogenesis. Mind. 2022;145:4193–201.
Monje M, Iwasaki A. The neurobiology of lengthy COVID. Neuron. 2022;110:3484–96.
Krasemann S, Haferkamp U, Pfefferle S, Woo MS, Heinrich F, Schweizer M, et al. The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. Stem Cell Rep. 2022;17:307–20.
Cocco A, Amami P, Desai A, Voza A, Ferreli F, Albanese A. Neurological options in SARS-CoV-2-infected sufferers with odor and style dysfunction. J Neurol. 2021;268:1570–72.
Schaeffer E, Postuma RB, Berg D. Prodromal PD: a brand new nosological entity. Prog Mind Res. 2020;252:331–56.
Li Ok, Wohlford-Lenane C, Perlman S, Zhao J, Jewell AK, Reznikov LR, et al. Center east respiratory syndrome coronavirus causes a number of organ harm and deadly illness in mice transgenic for human dipeptidyl peptidase 4. J Infect Dis. 2016;213:712–22.
Rethinavel HS, Ravichandran S, Radhakrishnan RK, Kandasamy M. COVID-19 and Parkinson’s illness: Defects in neurogenesis because the potential explanation for olfactory system impairments and anosmia. J Chem Neuroanat. 2021;115:101965.
Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a scientific presentation of mild-to-moderate types of the coronavirus illness (COVID-19): a multicenter European research. Eur Arch Otorhinolaryngol. 2020;277:2251–61.
Krashia P, Cordella A, Nobili A, La Barbera L, Federici M, Leuti A, et al. Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat mannequin of Parkinson’s illness. Nat Commun. 2019;10:3945.
Zhou J, Li C, Liu X, Chiu MC, Zhao X, Wang D, et al. An infection of bat and human intestinal organoids by SARS-CoV-2. Nat. Med. 2020;26:1077–83.
Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Intestine microbiota regulate motor deficits and neuroinflammation in a mannequin of Parkinson’s illness. Cell. 2016;167:1469–1480.e12.
Solar MF, Shen YQ. Dysbiosis of intestine microbiota and microbial metabolites in Parkinson’s Illness. Ageing Res Rev. 2018;45:53–61.
Dhar D, Mohanty A. Intestine microbiota and Covid-19- attainable hyperlink and implications. Virus Res. 2020;285:198018.
Borghammer P. How does parkinson’s illness start? Views on neuroanatomical pathways, prions, and histology. Mov Disord. 2018;33:48–57.
Baig AM, Khaleeq A, Ali U, Syeda H. Proof of the COVID-19 virus focusing on the CNS: tissue distribution, host-virus interplay, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11:995–98.
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a practical receptor for the SARS coronavirus. Nature. 2003;426:450–4.
Papa SM, Brundin P, Fung VSC, Kang UJ, Burn DJ, Colosimo C, et al. Impression of the COVID-19 pandemic on Parkinson’s illness and motion issues. Mov Disord. 2020;35:711–15.
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 might play a task within the respiratory failure of COVID-19 sufferers. J Med Virol. 2020;92:552–55.
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM construction of the 2019-nCoV spike within the prefusion conformation. Science. 2020;367:1260–63.
Chen X, Laurent S, Onur OA, Kleineberg NN, Fink GR, Schweitzer F, et al. A scientific assessment of neurological signs and problems of COVID-19. J. Neurol. 2021;268:392–402.
Brown EG, Chahine LM, Goldman SM, Korell M, Mann E, Kinel DR, et al. The impact of the COVID-19 pandemic on folks with Parkinson’s illness. J. Parkinsons Dis. 2020;10:1365–77.
Nataf S. An alteration of the dopamine artificial pathway is presumably concerned within the pathophysiology of COVID-19. J. Med Virol. 2020;92:1743–44.
Orru G, Conversano C, Malloggi E, Francesconi F, Ciacchini R, Gemignani A. Neurological problems of COVID-19 and attainable neuroinvasion pathways: a scientific assessment. Int J Environ Res Public Well being. 2020;17:6688.
Khalefah MM, Khalifah AM. Figuring out the connection between SARS-CoV-2 an infection, dopamine, and COVID-19 problems. J Taibah Univ Med Sci. 2020;15:550–53.
Kuba Ok, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. An important function of angiotensin changing enzyme 2 (ACE2) in SARS coronavirus-induced lung damage. Nat Med. 2005;11:875–9.
Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal hyperlink between ACE2 deficiency and SARS-CoV-2 an infection. Eur J Intern Med. 2020;76:14–20.
Achbani A, Sine H, Naciri A, Baba MA, Kharbach A, Bouchriti Y, et al. Can the 2019 novel coronavirus trigger Parkinson’s illness? Mov Disord. 2020;35:1102–03.
Pavel A, Murray DK, Stoessl AJ. COVID-19 and selective vulnerability to Parkinson’s illness. Lancet Neurol. 2020;19:719.
Victorino DB, Guimaraes-Marques M, Nejm M, Scorza FA, Scorza CA. COVID-19 and Parkinson’s illness: are we coping with short-term impacts or one thing worse? J Parkinsons Dis. 2020;10:899–902.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: think about cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–34.
DosSantos MF, Devalle S, Aran V, Capra D, Roque NR, Coelho-Aguiar JM, et al. Neuromechanisms of SARS-CoV-2: a assessment. Entrance Neuroanat. 2020;14:37.
Platt MP, Bolding KA, Wayne CR, Chaudhry S, Cutforth T, Franks KM, et al. Th17 lymphocytes drive vascular and neuronal deficits in a mouse mannequin of postinfectious autoimmune encephalitis. Proc Natl Acad Sci USA. 2020;117:6708–16.
Sadasivan S, Zanin M, O’Brien Ok, Schultz-Cherry S, Smeyne RJ. Induction of microglia activation after an infection with the non-neurotropic A/CA/04/2009 H1N1 influenza virus. PLoS ONE. 2015;10:e0124047.
Sulzer D. A number of hit hypotheses for dopamine neuron loss in Parkinson’s illness. Tendencies Neurosci. 2007;30:244–50.
Schirinzi T, Martella G, Pisani A. Double hit mouse mannequin of Parkinson’s illness. Oncotarget 2016;7:80109–10.
Rosen B, Kurtishi A, Vazquez-Jimenez GR, Moller SG. The Intersection of Parkinson’s illness, viral infections, and COVID-19. Mol Neurobiol. 2021;58:4477–86.
Chaudhry ZL, Klenja D, Janjua N, Cami-Kobeci G, Ahmed BY. COVID-19 and Parkinson’s illness: shared inflammatory pathways beneath oxidative stress. Mind Sci. 2020;10:807.
Hribar CA, Cobbold PH, Church FC. Potential function of vitamin D within the aged to withstand COVID-19 and to sluggish development of Parkinson’s illness. Mind Sci. 2020;10:284.
Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge Ok, Gong B, et al. Non-neuronal expression of SARS-CoV-2 entry genes within the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. 2020;6:eabc5801.
Semerdzhiev SA, Fakhree MAA, Segers-Nolten I, Blum C, Claessens M. Interactions between SARS-CoV-2 N-Protein and alpha-Synuclein speed up amyloid formation. ACS Chem Neurosci. 2022;13:143–50.
Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P. Triggers, facilitators, and aggravators: redefining Parkinson’s illness pathogenesis. Tendencies Neurosci. 2019;42:4–13.
Awogbindin IO, Ishola IO, St-Pierre MK, Service M, Savage JC, Di Paolo T, et al. Transforming microglia to a protecting phenotype in Parkinson’s illness? Neurosci Lett. 2020;735:135164.
Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57–69.
McManus RM, Heneka MT. Function of neuroinflammation in neurodegeneration: new insights. Alzheimers Res Ther. 2017;9:14.
Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dube M, et al. Human coronaviruses and different respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 2019;12:14.
Lang AE, Espay AJ. Illness modification in Parkinson’s illness: present approaches, challenges, and future issues. Mov Disord. 2018;33:660–77.
Li Q, Barres BA. Microglia and macrophages in mind homeostasis and illness. Nat Rev Immunol. 2018;18:225–42.
Meinhardt J, Streit S, Dittmayer C, Manitius RV, Radbruch H, Heppner FL. The neurobiology of SARS-CoV-2 an infection. Nat Rev Neurosci. 2024;25:30–42.
Choudhury A, Mukherjee S. In silico research on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. 2020;92:2105–13.
Biswas I, Khan GA. Coagulation issues in COVID-19: function of toll-like receptors. J Inflamm Res. 2020;13:823–28.
Dosch SF, Mahajan SD, Collins AR. SARS coronavirus spike protein-induced innate immune response happens by way of activation of the NF-kappaB pathway in human monocyte macrophages in vitro. Virus Res. 2009;142:19–27.
Xia Y, Zhang G, Kou L, Yin S, Han C, Hu J, et al. Reactive microglia improve the transmission of exosomal alpha-synuclein by way of toll-like receptor 2. Mind. 2021;144:2024–37.
Sureda A, Alizadeh J, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Jeandet P, et al. Endoplasmic reticulum as a possible therapeutic goal for covid-19 an infection administration? Eur J Pharmacol. 2020;882:173288.
Chan CP, Siu KL, Chin KT, Yuen KY, Zheng B, Jin DY. Modulation of the unfolded protein response by the extreme acute respiratory syndrome coronavirus spike protein. J Virol. 2006;80:9279–87.
Versteeg GA, van de Nes PS, Bredenbeek PJ, Spaan WJ. The coronavirus spike protein induces endoplasmic reticulum stress and upregulation of intracellular chemokine mRNA concentrations. J Virol. 2007;81:10981–90.
Liao Y, Fung TS, Huang M, Fang SG, Zhong Y, Liu DX. Upregulation of CHOP/GADD153 throughout coronavirus infectious bronchitis virus an infection modulates apoptosis by limiting activation of the extracellular signal-regulated kinase pathway. J Virol. 2013;87:8124–34.
Shchedrina VA, Zhang Y, Labunskyy VM, Hatfield DL, Gladyshev VN. Construction-function relations, physiological roles, and evolution of mammalian ER-resident selenoproteins. Antioxid Redox Sign. 2010;12:839–49.
Denaro CA, Haloush YI, Hsiao SY, Orgera JJ, Osorio T, Riggs LM, et al. COVID-19 and neurodegeneration: the mitochondrial connection. Ageing Cell. 2022;21:e13727.
Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL. The inflammatory response within the MPTP mannequin of Parkinson’s illness is mediated by mind angiotensin: relevance to development of the illness. J. Neurochem. 2009;109:656–69.
Jacobs W, Lammens M, Kerckhofs A, Voets E, Van San E, Van Coillie S, et al. Deadly lymphocytic cardiac harm in coronavirus illness 2019 (COVID-19): post-mortem reveals a ferroptosis signature. ESC Coronary heart Fail. 2020;7:3772–81.
Wang Y, Huang J, Solar Y, Stubbs D, He J, Li W, et al. SARS-CoV-2 suppresses mRNA expression of selenoproteins related to ferroptosis, endoplasmic reticulum stress and DNA synthesis. Meals Chem Toxicol. 2021;153:112286.
Kumar A. Expertise of video session in the course of the COVID-19 pandemic in aged inhabitants for Parkinson’s illness and motion issues. Postgrad Med J. 2021;97:117–18.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent type of nonapoptotic cell dying. Cell. 2012;149:1060–72.
Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the function of ferroptosis in most cancers. Nat Rev Clin Oncol. 2021;18:280–96.
Liu J, Kang R, Tang D. Signaling pathways and protection mechanisms of ferroptosis. FEBS J. 2022;289:7038–50.
Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and well being implications. Cell Res. 2021;31:107–25.
Hadian Ok, Stockwell BR. SnapShot: ferroptosis. Cell 2020;181:1188–88 e1.
Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P. Signaling pathways in Parkinson’s illness: molecular mechanisms and therapeutic interventions. Sign Transduct Goal Ther. 2023;8:73.
Do Van B, Gouel F, Jonneaux A, Timmerman Ok, Gele P, Petrault M, et al. Ferroptosis, a newly characterised type of cell dying in Parkinson’s illness that’s regulated by PKC. Neurobiol Dis. 2016;94:169–78.
Ito Ok, Eguchi Y, Imagawa Y, Akai S, Mochizuki H, Tsujimoto Y. MPP+ induces necrostatin-1- and ferrostatin-1-sensitive necrotic dying of neuronal SH-SY5Y cells. Cell Dying Discov. 2017;3:17013.
Kabiraj P, Valenzuela CA, Marin JE, Ramirez DA, Mendez L, Hwang MS, et al. The neuroprotective function of ferrostatin-1 beneath rotenone-induced oxidative stress in dopaminergic neuroblastoma cells. Protein J. 2015;34:349–58.
Devisscher L, Van Coillie S, Hofmans S, Van Rompaey D, Goossens Ok, Meul E, et al. Discovery of novel, drug-like ferroptosis inhibitors with in vivo efficacy. J Med Chem. 2018;61:10126–40.
Linkermann A, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F, et al. Synchronized renal tubular cell dying includes ferroptosis. Proc Natl Acad Sci USA. 2014;111:16836–41.
Jia F, Li H, Jiao Q, Li C, Fu L, Cui C, et al. Deubiquitylase OTUD3 prevents Parkinson’s illness by way of stabilizing iron regulatory protein 2. Cell Dying Dis. 2022;13:418.
Jia F, Tune N, Wang W, Du X, Chi Y, Jiang H. Excessive dietary iron complement induces the nigrostriatal dopaminergic neurons lesion in transgenic mice expressing mutant A53T human alpha-synuclein. Entrance Ageing Neurosci. 2018;10:97.
Edeas M, Saleh J, Peyssonnaux C. Iron: harmless bystander or vicious offender in COVID-19 pathogenesis? Int J Infect Dis. 2020;97:303–05.
Bellmann-Weiler R, Lanser L, Barket R, Rangger L, Schapfl A, Schaber M, et al. Prevalence and predictive worth of anemia and dysregulated iron homeostasis in sufferers with COVID-19 an infection. J Clin Med. 2020;9:2429.
Frazer DM, Anderson GJ. The regulation of iron transport. Biofactors. 2014;40:206–14.
Jia F, Liu H, Kang S. NCOA4-mediated ferritinophagy: a vicious offender in COVID-19 pathogenesis? Entrance Mol Biosci. 2021;8:761793.
Jia FJ, Han J. Liver damage in COVID-19: holds ferritinophagy-mediated ferroptosis accountable. World J Clin Instances. 2022;10:13148–56.
Dufrusine B, Valentinuzzi S, Bibbo S, Damiani V, Lanuti P, Pieragostino D, et al. Iron dyshomeostasis in COVID-19: biomarkers reveal a practical hyperlink to 5-lipoxygenase activation. Int J Mol Sci. 2022;24:15.
Ayton S, Lei P, Duce JA, Wong BX, Sedjahtera A, Adlard PA, et al. Ceruloplasmin dysfunction and therapeutic potential for Parkinson illness. Ann Neurol. 2013;73:554–9.
Wang B, Wang XP. Does ceruloplasmin defend towards neurodegenerative illnesses? Curr Neuropharmacol. 2019;17:539–49.
Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilio-da-Silva JV, et al. Elevated glucose ranges favor SARS-CoV-2 an infection and monocyte response by way of a HIF-1alpha/glycolysis-dependent axis. Cell Metab. 2020;32:437–446.e5.
Cuadrado A, Pajares M, Benito C, Jimenez-Villegas J, Escoll M, Fernandez-Gines R, et al. Can activation of NRF2 be a method towards COVID-19? Tendencies Pharmacol Sci. 2020;41:598–610.
Li X, Zhang Z, Wang Z, Gutierrez-Castrellon P, Shi H. Cell deaths: involvement within the pathogenesis and intervention remedy of COVID-19. Sign Transduct Goal Ther. 2022;7:186.
Mansour HM, Mohamed AF, El-Khatib AS, Khattab MM. Kinases management of regulated cell dying revealing druggable targets for Parkinson’s illness. Ageing Res Rev. 2023;85:101841.
Pang Q, Zheng L, Ren Z, Xu H, Guo H, Shan W, et al. Mechanism of ferroptosis and its relationships with different kinds of programmed cell dying: insights for potential therapeutic advantages in traumatic mind damage. Oxid Med Cell Longev. 2022;2022:1274550.
Li G, Wu R, Tong R, Bo B, Zhao Y, Gillen KM, et al. Quantitative measurement of metallic accumulation in mind of sufferers with wilson’s illness. Mov Disord. 2020;35:1787–95.
Ding XS, Gao L, Han Z, Eleuteri S, Shi W, Shen Y, et al. Ferroptosis in Parkinson’s illness: Molecular mechanisms and therapeutic potential. Ageing Res Rev. 2023;91:102077.
Almutary AM, Althunayyan S, Bagalb AS, Mady AF, Alenazi L, Mumtaz SA, et al. Deferoxamine within the administration of COVID-19 grownup sufferers admitted to ICU: a potential observational cohort research. Ann Med Surg. 2023;85:1468–74.
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.